Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers
Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers
批准号:
9925076
负责人:
Bin Chen
金额:
$16.91万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-05-01 至 2022-04-30
关键词:
AddressAdoptedAntineoplastic AgentsAwardBasal cell carcinomaBig DataBig Data MethodsBioinformaticsBiological MarkersCancer BiologyCancer PatientCancer cell lineCell LineClinicClinicalClinical TrialsCodeCommunitiesComputing MethodologiesConsumptionDataData SetDatabasesDiseaseEwings sarcomaExpression ProfilingGene ExpressionGene ProteinsGenomic Data CommonsGoalsIndividualKnowledgeMachine LearningMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of liverMentorsMeta-AnalysisMethodsMolecularMolecular ProfilingMusMutationNon-MalignantNormal tissue morphologyPatientsPatternPharmaceutical PreparationsPharmacogenomicsPrecision Medicine InitiativePrimary carcinoma of the liver cellsProbabilityProteomicsResearchResourcesSamplingScientistSourceSystemTherapeuticTimeTissue SampleTranslatingTreatment outcomeTumor TissueUniversitiesValidationWorkXenograft procedureactionable mutationbasebig-data sciencec-myc Genescancer cellcancer clinical trialcancer genomicscancer therapydata sharingdrug candidatedrug efficacydrug sensitivityefficacy testinggenetic signatureindividual patientindividualized medicinelearning classifiermalignant breast neoplasmmolecular markermouse modelnoveloncotypeoptimal treatmentspersonalized cancer therapypersonalized medicinepre-clinicalpredictive markerprotein expressionresponsestatisticstooltranscriptomicstriple-negative invasive breast carcinomatumor
中文摘要
项目总结
英文摘要
PROJECT SUMMARY
As a computational biologist, my long-term goal is to develop methods and tools to discover new or better
therapeutics for cancers. In the past few years, I have identified drug-repositioning candidates for a number of
primary cancers using Big Data approaches. These candidates have been validated successfully in preclinical
mouse models. To maximize the utility of Big Data, I plan to translate the findings into therapeutics; therefore, I
propose to develop methods to utilize transcriptomic, proteomic and pharmacogenomic data to inform
individualized therapy in cancers. Current preclinical and clinical approaches including the NCI MATCH trial
select therapies primarily based on actionable mutations, yet patients may have no actionable mutations or
multiple actionable mutations that are hard to prioritize, suggesting the need for other different types of
molecular biomarkers. The recent efforts have enabled the large-scale identification of various types of
molecular biomarkers through correlating drug sensitivity with molecular profiles of pre-treatment cancer cell
lines. Computational methods to match these biomarkers to individual patients to inform therapy in the clinic
are thus in high demand. The objective of this award is therefore to develop computational approaches to
identify therapeutics for individual patients by leveraging large-scale biomarkers identified from cancer cell
lines. Through conducing this research, I expect to expand my knowledge in cancer clinical trials, cancer
genomics, cancer biology, and statistics. To achieve the goal, I have gathered seven renowned experts from
different fields related to Big Data Science as mentors/advisors/collaborators: Primary Mentor Dr. Atul Butte in
translational bioinformatics from UCSF, Co-mentor Dr. Samuel So in cancer biology from Stanford University,
Co-mentor Dr. Mark Segal in statistics from UCSF, Advisor Dr. Andrei Goga in cancer biology from UCSF,
Advisor Dr. Laura Esserman in breast cancer trials from UCSF, Collaborator Dr. John Gordan in liver cancer
trials from UCSF and Collaborator Dr. Xin Chen in cancer biology from UCSF. With the support from my world-
class mentors, advisors and collaborators, this award will prepare me to be a leader in developing big data
methods that are broadly impactful.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
AICM: A Genuine Framework for Correcting Inconsistency Between Large Pharmacogenomics Datasets.
AICM:纠正大型药物基因组数据集之间不一致的真正框架。
DOI:
--
发表时间:
2019
期刊:
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing
影响因子:
--
作者:
[Hu,ZhiyueTom, Ye,Yuting, Newbury,PatrickA, Huang,Haiyan, Chen,Bin]
通讯作者:
Chen,Bin
DOI:
10.1038/s41596-020-00430-z
发表时间:
2021-03
期刊:
Nature protocols
影响因子:
14.8
作者:
[Zeng B, Glicksberg BS, Newbury P, Chekalin E, Xing J, Liu K, Wen A, Chow C, Chen B]
通讯作者:
Chen B
DOI:
10.1016/j.isci.2022.105068
发表时间:
2022-10-21
期刊:
ISCIENCE
影响因子:
5.8
作者:
[Xing, Jing, Shankar, Rama, Ko, Meehyun, Zhang, Keke, Zhang, Sulin, Drelich, Aleksandra, Paithankar, Shreya, Chekalin, Eugene, Chua, Mei-Sze, Rajasekaran, Surender, Tseng, Chien-Te Kent, Zheng, Mingyue, Kim, Seungtaek, Chen, Bin]
通讯作者:
Chen, Bin
Selecting precise reference normal tissue samples for cancer research using a deep learning approach.
使用深度学习方法为癌症研究选择精确的参考正常组织样本。
DOI:
10.1186/s12920-018-0463-6
发表时间:
2019
期刊:
BMC medical genomics
影响因子:
2.7
作者:
[Zeng,WilliamZD, Glicksberg,BenjaminS, Li,Yangyan, Chen,Bin]
通讯作者:
Chen,Bin
Published Anti-SARS-CoV-2 In Vitro Hits Share Common Mechanisms of Action that Synergize with Antivirals.
已发表的抗 SARS-CoV-2 体外热门药物具有与抗病毒药物协同作用的共同作用机制。
DOI:
10.1101/2021.03.04.433931
发表时间:
2021
期刊:
bioRxiv : the preprint server for biology
影响因子:
--
作者:
[Xing,Jing, Paithankar,Shreya, Liu,Ke, Uhl,Katie, Li,Xiaopeng, Ko,Meehyun, Kim,Seungtaek, Haskins,Jeremy, Chen,Bin]
通讯作者:
Chen,Bin
virtual compound screening using gene expression
-
批准号:10418186
-
项目类别:
-
资助金额:$42.08万
-
财政年份:2022
-
负责人:Bin Chen
-
依托单位:
virtual compound screening using gene expression
-
批准号:10673837
-
项目类别:
-
资助金额:$42.08万
-
财政年份:2022
-
负责人:Bin Chen
-
依托单位:
Equipment Purchases for R01GM145700
-
批准号:10795418
-
项目类别:
-
资助金额:$10.32万
-
财政年份:2022
-
负责人:Bin Chen
-
依托单位:
A postdoctoral training program for impactful careers in stem cell biology
-
批准号:10592329
-
项目类别:
-
资助金额:$23.68万
-
财政年份:2022
-
负责人:Bin Chen
-
依托单位:
Drug biomarker resources for precise translational research
-
批准号:10056488
-
项目类别:
-
资助金额:$5.82万
-
财政年份:2020
-
负责人:Bin Chen
-
依托单位:
Repurpose open data to discover therapeutics for understudied diseases
-
批准号:10461787
-
项目类别:
-
资助金额:$41.52万
-
财政年份:2019
-
负责人:Bin Chen
-
依托单位:
Repurpose open data to discover therapeutics for understudied diseases
-
批准号:10704561
-
项目类别:
-
资助金额:$41.83万
-
财政年份:2019
-
负责人:Bin Chen
-
依托单位:
Repurpose open data to discover therapeutics for understudied diseases
-
批准号:10669357
-
项目类别:
-
资助金额:$0.64万
-
财政年份:2019
-
负责人:Bin Chen
-
依托单位:
Repurpose open data to discover therapeutics for understudied diseases
-
批准号:10713005
-
项目类别:
-
资助金额:$34.67万
-
财政年份:2019
-
负责人:Bin Chen
-
依托单位:
Repurpose open data to discover therapeutics for understudied diseases
-
批准号:10231115
-
项目类别:
-
资助金额:$41.63万
-
财政年份:2019
-
负责人:Bin Chen
-
依托单位:
Lineage Progression of Cortical Neural Stem Cells
-
批准号:10676226
-
项目类别:
-
资助金额:$61.92万
-
财政年份:2015
-
负责人:Bin Chen
-
依托单位:
Lineage Progression of Cortical Neural Stem Cells
-
批准号:10451726
-
项目类别:
-
资助金额:$62.03万
-
财政年份:2015
-
负责人:Bin Chen
-
依托单位:
Lineage progression of cortical neural stem cells
-
批准号:10313884
-
项目类别:
-
资助金额:$63.15万
-
财政年份:2015
-
负责人:Bin Chen
-
依托单位:
Determining the lineage progression of embryonic and adult neural stem cells
-
批准号:8964493
-
项目类别:
-
资助金额:$32.12万
-
财政年份:2015
-
负责人:Bin Chen
-
依托单位:
Pyrethroid Resistance in Malaria Mosquito Anopheles sinensis
-
批准号:8146566
-
项目类别:
-
资助金额:$10.8万
-
财政年份:2011
-
负责人:Bin Chen
-
依托单位:
Transcriptional regulation of neuronal identity and connectivity
-
批准号:8163606
-
项目类别:
-
资助金额:$37.15万
-
财政年份:2011
-
负责人:Bin Chen
-
依托单位:
Transcriptional regulation of neuronal identity and connectivity
-
批准号:8290289
-
项目类别:
-
资助金额:$37.09万
-
财政年份:2011
-
负责人:Bin Chen
-
依托单位:
Transcriptional regulation of neuronal identity and connectivity
-
批准号:8449314
-
项目类别:
-
资助金额:$35.54万
-
财政年份:2011
-
负责人:Bin Chen
-
依托单位:
Transcriptional regulation of neuronal identity and connectivity
-
批准号:8824568
-
项目类别:
-
资助金额:$36.85万
-
财政年份:2011
-
负责人:Bin Chen
-
依托单位:
海外基金